Supra-Iliac Anterior Quadratus Lumborum Block and Pericapsular Nerve Group (PENG) Block for Analgesia After Total Hip Arthroplasty

NCT07606794 | Recruiting

• 1 other identifier: 36265PR1/4/26
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to compare the analgesic efficacy of supra-iliac anterior quadratus lumborum block (SA-QLB) and pericapsular nerve group (PENG) block in patients undergoing total hip arthroplasty (THA).

Conditions

Supra-Iliac Anterior Quadratus Lumborum Block; Pericapsular Nerve Group Block; Analgesia; Total Hip Arthroplasty

Outcome Measures

Primary Outcomes (1)

• Degree of pain

  Each patient will be instructed about postoperative pain assessment with visual analog scale (VAS). VAS (0 represents "no pain" while 10 represents "the worst pain imaginable")

  12 hours postoperatively

Secondary Outcomes (5)

• Total morphine consumption

  48 hours postoperatively

• Time to the first rescue analgesia

  48 hours postoperatively

• Time to ambulation

  Till the first successful mobilization (Up to 4 hours)

• Length of hospital stay

  Till discharge from the hospital (Up to 2 weeks)

• Incidence of adverse events

  24 hours postoperatively

Study Arms (2)

Group SA- QLB

EXPERIMENTAL

Patients will receive a supra-iliac anterior quadratus lumborum block (SA-QLB) using 20mL of bupivacaine 0.25%.

Other: Supra-iliac anterior quadratus lumborum block

Group PENG

EXPERIMENTAL

Patients will receive an ultrasound-guided pericapsular nerve group (PENG) block using 20mL of bupivacaine 0.25%.

Other: Pericapsular nerve group block

Interventions

Pericapsular nerve group block OTHER

Patients will receive an ultrasound-guided pericapsular nerve group (PENG) block using 20mL of bupivacaine 0.25%.

Group PENG

Supra-iliac anterior quadratus lumborum block OTHER

Patients will receive a supra-iliac anterior quadratus lumborum block (SA-QLB) using 20mL of bupivacaine 0.25%.

Group SA- QLB

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age from 18 to 75 years.
• Both sexes.
• American Society of Anesthesiologists (ASA) classification I-III.
• Scheduled for primary elective unilateral total hip arthroplasty (THA) under spinal anesthesia.

You may not qualify if:

• Known allergies to the drugs used.
• Infection at the injection site.
• Bleeding disorders.
• Recognized neuromuscular disorders.
• Opioid addiction or dependence.
• Contraindications to regional anesthesia or peripheral nerve blockade.
• Body mass index (BMI) \> 40 kg/m².
• Associated decompensated cardiac, hepatic, respiratory, or renal diseases.

Sponsors & Collaborators

• Tanta University: lead

Study Sites (1)

Tanta University

Tanta, El-Gharbia, 31527, Egypt

RECRUITING

MeSH Terms

Conditions

Agnosia

Condition Hierarchy (Ancestors)

Perceptual Disorders; Neurobehavioral Manifestations; Neurologic Manifestations; Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Mohammed S Elsharkawy, MD

CONTACT

00201148207870; mselsharkawy@med.tanta.edu.eg

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.

Study Record Dates

• First Submitted: May 19, 2026
• First Posted: May 26, 2026
• Study Start: May 23, 2026
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): October 1, 2026
• Last Updated: May 27, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: After the end of study for one year.
• Access Criteria: The data will be available upon a reasonable request from the corresponding author.

Locations

EG (1)